S. 1523 · 117th Congress
Drug Price Transparency Act of 2021
- Stage
- In committee
- Sponsor
- Mike Braun
- Introduced
- 2021-04-29
- Latest action
- 2021-04-29 · Introduced in Senate
Summary
Drug Price Transparency Act of 2021
This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.